MT Dermaceuticals believes strongly in following the scientific method to ensure that our products and protocols are as safe and effective as possible.
The following information details the Clinical Trials and Case Studies conducted on psoriasis, eczema and many other chronic skin conditions. These have been conducted both in Australia and overseas.
2000 – 2010
Report of the study of the “Dr Michaels” topical product family in psoriasis. (Australian Trial)
ABSTRACT – that appeared in the publication of the: JEADV (Journal of the European Academy of Dermatology and Venereology) – Volume 18. Number 6. November 2004. P061 – Prospective, randomized controlled double-blind study on the efficacy and safety of a series of herbal skin-care products for stable chronic plaque psoriasis.
PDF: No Abstract available
The Results Of Attestation Study Of Effectiveness Dr. Michaels Psoriasis Products (undertaken during the years 2005-2008)
Conducted by Prof. MUDr. Jana Hercogová, CSc.
Very good results were achieved with chronic psoriasis.
The following specialists participated in this study:
|S.No||Name of Doctor / Professor||Hospital/Institution|
|1||Head Physician MUDr. Št?pánka ?apková||Faculty Hospital Motol|
|2||MUDr. Michaela Havlí?ková||Faculty Hospital Královské Vinohrady|
|3||Prof. MUDr. Karel Pizinger||Faculty Hospital in Plze?|
|4||Head Physician MUDr. Jaroslav Hoffmann||Central Military Hospital in Praha|
|5||Doc. MUDr. Karel Ettler, CSc.||Faculty Hospital in Hradec Králové|
|6||Head Physician MUDr. Hana Duchková, DrSc||Dermatology Sanatorium in Ústí nad Labem|
|7||Head Physician MUDr. Hana Bu?ková, Ph.D.||Faculty Hospital in Brno|
|8||Head Physician MUDr. Hana Zelenková, Ph.D||DOST – Svidník, Slovensko (Slovakia)|
|9||Prof. MUDr. František Novotný, DrSc.||Prague Dermatology Center|
|10||Prof. MUDr. Jana Hercogová, CSc.||Faculty Hospital Bulovka|
* Prof. Novotný was monitoring patients during the years 2005–2008. The results from other dermatology workplaces come from tests conducted during the year 2008.
Average success ratio: 82.3%